User: Guest  Login
Document type:
journal article 
Author(s):
Eckel, F; Schmelz, R; Erdmann, J; Mayr, M; Lersch, C 
Title:
Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. 
Abstract:
The antitumor effect of gemcitabine is not dose-response related but schedule dependent. Here we report a phase II trial of a weekly 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic cancer. Patients with histologically proven, measurable, and irresectable pancreatic adenocarcinoma were treated with gemcitabine at a dose of 100 mg/m2 infused over 24 hr on days 1, 8, and 15. Treatment was repeated every 28 days until progression of disease or limiting toxic...    »
 
Journal title abbreviation:
Cancer Invest 
Year:
2003 
Journal volume:
21 
Journal issue:
Pages contribution:
690-4 
Language:
eng 
Print-ISSN:
0735-7907 
TUM Institution:
II. Medizinische Klinik und Poliklinik